imatinib mesylate has been researched along with Neointima in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, L; Du, J; Fan, X; Kong, X; Li, A; Liang, L; Lin, L; Song, J | 1 |
| Hartney, TJ; Jun, JY; Pichavaram, P; Segar, L; Shawky, NM | 1 |
2 other study(ies) available for imatinib mesylate and Neointima
| Article | Year |
|---|---|
Treatment with imatinib was useful to delay the neointimal hyperplasia of aortocaval fistula in adenine-induced renal failure rats.
Topics: Animals; Constriction, Pathologic; Fistula; Hyperplasia; Imatinib Mesylate; Neointima; Proto-Oncogene Proteins c-kit; Rats; Renal Insufficiency | 2023 |
Imatinib improves insulin resistance and inhibits injury-induced neointimal hyperplasia in high fat diet-fed mice.
Topics: Animals; Diet, High-Fat; Femoral Artery; Hyperplasia; Imatinib Mesylate; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Neointima; Protein Kinase Inhibitors | 2021 |